Physician profile
Alhareth Alsayed
NPI 1447601059
$1,792.83
in general payments reported to CMS, 2019-2025
18 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $331 · 2021: $255 · 2022: $141 · 2023: $146 · 2024: $281 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482 · Education: $84.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $481.61 |
| Education | $84.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $400.23 | 2019-2023 | Faslodex |
| Merck Sharp & Dohme LLC | $313.98 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $222.85 | 2019-2025 | |
| Epizyme, INC. | $196.67 | 2021 | |
| Lilly USA, LLC | $116.66 | 2020-2025 | Verzenio |
| Amgen INC. | $94.42 | 2019 | |
| Seagen INC. | $74.99 | 2019 | |
| Progenics Pharmaceuticals, INC. | $66.94 | 2025 | |
| Celgene Corporation | $61.00 | 2024 | Reblozyl, Pomalyst |
| Pfizer INC. | $40.93 | 2020-2025 | |
| Eisai INC. | $39.20 | 2019-2021 | |
| Incyte Corporation | $34.31 | 2020-2023 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $32.66 | 2024 | Opdualag |
| Genmab U.S., INC. | $25.05 | 2024 | Epkinly |
| Abbvie INC. | $24.00 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $23.80 | 2022 | |
| Tactile Systems Technology INC | $13.35 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alhareth Alsayed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.